Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 18, 2012, Pages 8188-8192

  Han, Younghue ^a   Han, Minsoo ^a,b   Shin, Dongyun ^a,c   Song, Chiman ^a   Hahn, Hoh Gyu ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea University   (South Korea)

^c Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; AZETIDINE DERIVATIVE; FLUOXETINE; NISOXETINE; VANOXERINE;

ALKYLATION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG SCREENING; DRUG SYNTHESIS; GRIGNARD REACTION; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OXIDATION KINETICS; SUBSTITUTION REACTION; SWERN OXIDATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZETIDINES; BEHAVIOR, ANIMAL; DRUG DESIGN; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEUROTRANSMITTER UPTAKE INHIBITORS;

EID: 84866840102     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3008294     Document Type: Article

References (27)

1. Prins, J.; Olivier, B.; Korte, S. M. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited Expert Opin. Invest. Drugs 2011, 20, 1107-1130
2. Kulkarni, S. K.; Dhir, A. Current investigational drugs for major depression Expert Opin. Invest. Drugs 2009, 18, 767-788
3. Millan, M. J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 2009, 6, 53-77
4. Skolnick, P.; Basile, A. S. Triple reuptake inhibitors as antidepressants Drug Discovery Today: Ther. Strategies 2006, 3, 489-494
5. Holtzheimer, P. E., III; Nemeroff, C. B. Advances in the treatment of depression Neurotherapeutics 2006, 3, 42-56
6. Zisook, S.; Rush, A. J.; Haight, B. R.; Clines, D. C.; Rockett, C. B. Use of bupropion in combination with serotonin reuptake inhibitors Biol. Psychiatry 2006, 59, 203-210
7. Papakostas, G. I.; Worthington, J. J., III; Iosifescu, D. V.; Kinrys, G.; Burns, A. M.; Fisher, L. B.; Homberger, C. H.; Mischoulon, D.; Fava, M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder Depression Anxiety 2006, 23, 178-181
8. Millan, M. J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 2006, 110, 135-370
9. Skolnick, P. Dopamine and Depression. In Dopamine and Glutamate in Psychiatric Disorders; Schmidt, W. J.; Reith, M. E. A., Eds.; Humana Press Inc.: Totowa, NJ, 2005; pp 199-214.
10. Fava, M. Augmentation and combination strategies in treatment resistant depression J. Clin. Psychiatry 2001, 62, 4-11
11. Prica, C.; Hascoet, M.; Bourin, M. Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? Behav. Brain Res. 2008, 194, 92-99
12. Beer, B.; Stark, J.; Krieter, P.; Czobor, P.; Beer, G.; Lippa, A.; Skolnick, P. DOV 216,303, a "Triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile J. Clin. Pharmacol 2004, 44, 1360-1367
13. Skolnick, P.; Popik, P.; Janowsky, A.; Beer, B.; Lippa, A. S. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci. 2003, 73, 3175-3179
14. Chen, Z.; Skolnick, P. Triple uptake inhibitors: therapeutic potential in depression and beyond Expert Opin. Invest. Drugs 2007, 16, 1365-1377
15. Wong, D. T.; Perry, K. W.; Bymaster, F. P. The discovery of fluoxetine hydrochloride (Prozac) Nature Rev. Drug Discovery 2005, 4, 764-774
16. Bymaster, F. P.; Katner, J. S.; Nelson, D. J.; Hemrick-Luecke, S. K.; Threlkeld, P. J.; Heiligenstein, J. H.; Morin, S. M.; Gehlert, D. R.; Perry, K. W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder Neuropsychopharmacology 2002, 27, 699-711
17. Montgomery, S.; Ferguson, J. M.; Schwartz, G. E. The antidepressant efficacy of reboxetine in patients with severe depression J. Clin. Psychopharmacol. 2003, 23, 45-50
18. Schueler, Y.-B.; Koesters, M.; Wieseler, B.; Grouven, U.; Kromp, M.; Kerekes, M. F.; Kreis, J.; Kaiser, T.; Becker, T.; Weinmann, S. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data Acta Psychiatr. Scand. 2011, 123, 247-265
19. 1A partial agonists Bioorg. Med. Chem. Lett. 2011, 21, 865-868
20. Beadle, C. D.; Cases-Thomas, M. J.; Clark, B. P.; Callagher, P. T.; Masters, J. J.; Timms, G. H.; Walter, M. W.; Whatton, M. A.; Wood, V. A.; Gilmore, J. 3-Aminopyrrolidines as inhibitors of monoamine uptake. PCT Int. Appl. WO 2005000811 A1, 2005.
21. Enyedy, I. J.; Zaman, W. A.; Sakamuri, S.; Kozikowski, A. P.; Johnson, K. M.; Wang, S. Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors Bioorg. Med. Chem. Lett. 2001, 11, 1113-1118
22. Bennett, D. A.; Wichems, C. H.; Hollingsworth, C. K.; Davies, H. M. L.; Thornley, C.; Sexton, T.; Childers, S. R. Novel 2-substituted cocaine analogs: uptake and ligand binding studies at dopamine, serotonin and norepinephrine transport sites in the rat brain J. Pharmacol. Exp. Ther. 1995, 272, 1176-1186
23. Zhou, J.; He, H.; Johnson, K. M.; Ye, Y.; Kozikowski, A. P. Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization J. Med. Chem. 2004, 47, 5821-5824
24. Jørgensen, S.; Nielsen, E. Ø.; Peters, D.; Dyhring, T. Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity J. Neurosci. Methods 2008, 169, 168-176
25. Choi, K. H.; Song, C.; Shin, D.; Park, S. hERG channel blockade by externally applied quaternary ammonium derivatives Biochim. Biophys. Acta 2011, 1808, 1560-1566
26. Reichel, A. The role of blood-brain barrier studies in the pharmaceutical industry Curr. Drug Metab. 2006, 7, 183-203
27. Porsolt, R. D.; Pichon, M. L.; Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments Nature 1977, 266, 730-732